Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Medartis Holding AG ( (CH:MED) ) is now available.
Medartis reported 2025 total sales of CHF 269.3 million, with core sales up 15.7% organically at constant exchange rates and double-digit growth across all regions, led by EMEA, while maintaining a core EBITDA margin of 18.4% despite currency headwinds and U.S. tariffs. The consolidation of KeriMedical and NeoOrtho delivered strong value-enhancing growth, expanded the group’s multi-tier market reach and lifted Medartis’ addressable market by more than CHF 800 million, while the planned acquisition of Belgian custom-implant specialist CADskills strengthens its position in personalized titanium implants and small-bone prostheses and underpins expectations of continued high-teens profitability and robust organic growth in 2026.
The most recent analyst rating on (CH:MED) stock is a Hold with a CHF95.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.
More about Medartis Holding AG
Medartis Holding AG is a Swiss orthopaedic company focused on implants and instruments for head and extremities surgery. The group is expanding from its traditional Swiss-precision, single-brand model into a decentralized, multi-brand platform addressing premium and value segments, particularly in Europe, the U.S., Latin America and Asia-Pacific.
Average Trading Volume: 4,490
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.14B
For an in-depth examination of MED stock, go to TipRanks’ Overview page.